Literature DB >> 30065020

End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.

Christopher Melani1, Mark Roschewski1, Wyndham H Wilson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30065020      PMCID： PMC6068019          DOI： 10.3324/haematol.2018.199547

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Authors:  Michael Schaapveld; Berthe M P Aleman; Anna M van Eggermond; Cécile P M Janus; Augustinus D G Krol; Richard W M van der Maazen; Judith Roesink; John M M Raemaekers; Jan Paul de Boer; Josée M Zijlstra; Gustaaf W van Imhoff; Eefke J Petersen; Philip M P Poortmans; Max Beijert; Marnix L Lybeert; Ina Mulder; Otto Visser; Marieke W J Louwman; Inge M Krul; Pieternella J Lugtenburg; Flora E van Leeuwen
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

2.  Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

Authors:  Lisa Giulino-Roth; Tara O'Donohue; Zhengming Chen; Nancy L Bartlett; Ann LaCasce; William Martin-Doyle; Matthew J Barth; Kimberly Davies; Kristie A Blum; Beth Christian; Carla Casulo; Sonali M Smith; James Godfrey; Amanda Termuhlen; Matthew J Oberley; Sarah Alexander; Sheila Weitzman; Burton Appel; Benjamin Mizukawa; Jakub Svoboda; Zeinab Afify; Melinda Pauly; Hema Dave; Rebecca Gardner; Deborah M Stephens; William A Zeitler; Christopher Forlenza; Jennifer Levine; Michael E Williams; Jody L Sima; Catherine M Bollard; John P Leonard
Journal:  Br J Haematol       Date:  2017-10-29       Impact factor: 6.998

3.  Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Authors:  Carrie A Thompson; Herve Ghesquieres; Matthew J Maurer; James R Cerhan; Pierre Biron; Stephen M Ansell; Catherine Chassagne-Clément; David J Inwards; Thérèse Gargi; Patrick B Johnston; Emmanuelle Nicolas-Virelizier; William R Macon; Marie Peix; Ivana N Micallef; Catherine Sebban; Grzegorz S Nowakowski; Luis F Porrata; George J Weiner; Thomas E Witzig; Thomas M Habermann; Brian K Link
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

4.  Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

Authors:  Tarec Christoffer El-Galaly; Lasse Hjort Jakobsen; Martin Hutchings; Peter de Nully Brown; Herman Nilsson-Ehle; Elisabeth Székely; Karen Juul Mylam; Viktoria Hjalmar; Hans Erik Johnsen; Martin Bøgsted; Mats Jerkeman
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

5.  [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Authors:  Maurizio Martelli; Luca Ceriani; Emanuele Zucca; Pier Luigi Zinzani; Andrés J M Ferreri; Umberto Vitolo; Caterina Stelitano; Ercole Brusamolino; Maria Giuseppina Cabras; Luigi Rigacci; Monica Balzarotti; Flavia Salvi; Silvia Montoto; Armando Lopez-Guillermo; Erica Finolezzi; Stefano A Pileri; Andrew Davies; Franco Cavalli; Luca Giovanella; Peter W M Johnson
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

6.  R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.

Authors:  Nirav N Shah; Aniko Szabo; Scott F Huntington; Narendranath Epperla; Nishitha Reddy; Siddhartha Ganguly; Julie Vose; Cynthia Obiozor; Fahad Faruqi; Alexandra E Kovach; Luciano J Costa; Ana C Xavier; Ryan Okal; Abraham S Kanate; Nilanjan Ghosh; Mohamed A Kharfan-Dabaja; Lauren Strelec; Mehdi Hamadani; Timothy S Fenske; Oscar Calzada; Jonathon B Cohen; Julio Chavez; Jakub Svoboda
Journal:  Br J Haematol       Date:  2017-12-19       Impact factor: 6.998

7.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

8.  Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.

Authors:  Nickhill Bhakta; Qi Liu; Frederick Yeo; Malek Baassiri; Matthew J Ehrhardt; Deo K Srivastava; Monika L Metzger; Matthew J Krasin; Kirsten K Ness; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet Oncol       Date:  2016-07-25       Impact factor: 41.316

9.  End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Authors:  Christopher Melani; Ranjana Advani; Mark Roschewski; Kelsey M Walters; Clara C Chen; Lucia Baratto; Mark A Ahlman; Milos D Miljkovic; Seth M Steinberg; Jessica Lam; Margaret Shovlin; Kieron Dunleavy; Stefania Pittaluga; Elaine S Jaffe; Wyndham H Wilson
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941
  9 in total
  1 in total

1.  Continuous infusion chemotherapy, radiotherapy, and FDG-PET are feasible during extracorporeal membrane oxygenation.

Authors:  Seth J Rotz; Francisco A Almeida; Shlomo Koyfman; Sudhir Krishnan; Guramrinder Singh Thind; William Phillips; James Yun; Anthony Zembillas; Mark Zahniser; Alejandro Bribriesco
Journal:  Pediatr Blood Cancer       Date:  2020-07-16       Impact factor: 3.167
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.